EyePoint Pharmaceuticals, Inc. (EYPT) Financial Ratios
23 years of historical data (2003–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low4.2·High13.2
P/FCF
N/A
—
5yr avg: N/A
30Y Low6.9·High11.4
P/B Ratio
↑
3.21
↑+31% vs avg
5yr avg: 2.45
30Y Low1.0·High19.4
ROE
↓
-72.2%
↑-27% vs avg
5yr avg: -57.0%
30Y Low-425%·High33%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EYPT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
EyePoint Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $1.3B | $419M | $899M | $131M | $352M | $84M | $162M | $96M | $60M | $89M |
| Enterprise Value | $1.0B | $1.3B | $342M | $623M | $81M | $213M | $81M | $190M | $75M | $61M | $74M |
| P/E Ratio → | -4.23 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 35.82 | 42.66 | 9.69 | 19.54 | 3.15 | 9.53 | 2.45 | 7.94 | 32.47 | 8.02 | 55.24 |
| P/B Ratio | 3.21 | 4.37 | 1.25 | 3.38 | 1.36 | 1.91 | 4.56 | 19.41 | 8.23 | 4.53 | 4.29 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | 479.50 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EYPT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 40.08 | 7.89 | 13.53 | 1.96 | 5.76 | 2.34 | 9.33 | 25.22 | 8.07 | 45.79 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
EYPT Profitability
Margins and return-on-capital ratios measuring operating efficiency
EyePoint Pharmaceuticals, Inc. earns an operating margin of -776.0%. Operating margins have compressed from -163.1% to -776.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -72.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.4% | 93.4% | 91.4% | 89.9% | 79.9% | 77.9% | 83.1% | 86.8% | -524.9% | 100.0% | 49.7% |
| Operating Margin | -776.0% | -776.0% | -337.1% | -163.1% | -240.6% | -149.6% | -108.3% | -235.0% | -887.3% | -246.4% | -1344.1% |
| Net Profit Margin | -739.4% | -739.4% | -302.4% | -153.8% | -247.0% | -158.1% | -131.8% | -278.9% | -1795.7% | -245.2% | -1330.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -72.2% | -72.2% | -43.4% | -39.0% | -72.8% | -57.6% | -337.9% | -567.4% | -425.0% | -108.0% | -97.4% |
| ROA | -59.3% | -59.3% | -33.8% | -26.4% | -46.1% | -32.9% | -55.1% | -78.5% | -117.7% | -73.5% | -67.3% |
| ROIC | -75.5% | -75.5% | -88.0% | -303.9% | -162.3% | -139.1% | -108.9% | -266.5% | -993.5% | -144.3% | -332.8% |
| ROCE | -69.9% | -69.9% | -44.1% | -34.3% | -51.7% | -34.9% | -53.9% | -85.9% | -82.9% | -93.1% | -78.4% |
EYPT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $102M exceeds total debt of $21M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.06 | 0.02 | 0.48 | 0.21 | 2.21 | 6.07 | 1.48 | 1.30 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.26 | -0.23 | -1.04 | -0.51 | -0.76 | -0.21 | 3.41 | -1.84 | 0.03 | -0.73 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -7376.79 | -7376.79 | -9340.43 | -55.71 | -31.06 | -9.63 | -5.26 | -8.20 | -54.19 | -72.85 | — |
Net cash position: cash ($102M) exceeds total debt ($21M)
EYPT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
EyePoint Pharmaceuticals, Inc.'s current ratio of 8.88x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 5.45x to 8.88x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.88 | 8.88 | 7.81 | 5.45 | 5.00 | 10.05 | 4.24 | 3.62 | 1.84 | 3.35 | 5.88 |
| Quick Ratio | 8.83 | 8.83 | 7.77 | 5.39 | 4.92 | 9.90 | 3.88 | 3.44 | 1.86 | 3.40 | 5.98 |
| Cash Ratio | 8.27 | 8.27 | 7.56 | 5.23 | 4.19 | 8.94 | 3.02 | 1.93 | 1.79 | 3.19 | 5.69 |
| Asset Turnover | — | 0.09 | 0.10 | 0.13 | 0.23 | 0.14 | 0.38 | 0.28 | 0.04 | 0.40 | 0.05 |
| Inventory Turnover | 1.14 | 1.14 | 1.61 | 1.19 | 2.88 | 2.26 | 1.09 | 1.26 | — | — | — |
| Days Sales Outstanding | — | 7.57 | 5.12 | 6.38 | 136.67 | 181.36 | 100.19 | 203.75 | 43.51 | 17.09 | 56.55 |
EYPT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
EyePoint Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% |
| Shares Outstanding | — | $73M | $56M | $39M | $37M | $29M | $13M | $10M | $5M | $4M | $3M |
Peer Comparison
Compare EYPT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EYPTYou | $1B | -4.2 | — | — | 93.4% | -776.0% | -72.2% | -75.5% | — |
 OCUL | $2B | -6.8 | — | — | 87.3% | -521.0% | -54.9% | — | — |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 ALDX | $104M | -1.8 | — | — | — | — | -58.5% | -369.4% | — |
 KALA | $617676 | -0.0 | — | — | — | — | -388.3% | — | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 AVXL | $289M | -5.8 | — | — | — | — | -43.1% | — | — |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 REPL | $266M | -1.1 | — | — | — | — | -62.6% | -51.9% | — |
 BHVN | $1B | -1.4 | — | — | — | — | -310.8% | -242.1% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 23 years · Updated daily
See EYPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EYPT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EYPT vs OCUL
Side-by-side business, growth, and profitability comparison vs Ocular Therapeutix, Inc..
Start ComparisonEYPT — Frequently Asked Questions
Quick answers to the most common questions about buying EYPT stock.
What is EyePoint Pharmaceuticals, Inc.'s P/E ratio?
EyePoint Pharmaceuticals, Inc.'s current P/E ratio is -4.2x. The historical average is 13.0x.
What is EyePoint Pharmaceuticals, Inc.'s ROE?
EyePoint Pharmaceuticals, Inc.'s return on equity (ROE) is -72.2%. The historical average is -90.9%.
Is EYPT stock overvalued?
Based on historical data, EyePoint Pharmaceuticals, Inc. is trading at a P/E of -4.2x. Compare with industry peers and growth rates for a complete picture.
What are EyePoint Pharmaceuticals, Inc.'s profit margins?
EyePoint Pharmaceuticals, Inc. has 93.4% gross margin and -776.0% operating margin.